The Food and Drug Administration (FDA) is recommending that manufacturers stop using the labels "latex-free" or "does not contain latex" due to the scientific inaccuracy of these claims.
Merck announced results from the Phase 3 KEYNOTE-006 study investigating Keytruda (pembrolizumab) vs. ipilimumab in the first-line treatment of patients with advanced melanoma.
Pfizer announced results from two Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program for tofacitinib citrate in adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Celgene announced results from the ESTEEM Phase 3 clinical program for Otezla (apremilast) in patients with moderate to severe plaque psoriasis.
Over 25% of patients with acne did not obtain medications prescribed by their dermatologists, according to a survey by Wake Forest Baptist Medical Center researchers.
Galderma announced positive Phase 3 results for adapalene 0.3%/benzoyl peroxide 2.5% (0.3% A/BPO) topical gel.
Two common antibiotics have been shown to be equally effective in treating uncomplicated community-acquired skin infections like methicillin-resistant Staphylococcus aureus (MRSA), according to a new study in the New England Journal of Medicine.
An antihypertensive was found to reduce side effects from corticosteroid-based creams used for certain skin diseases, reports a study published in the Journal of Investigative Dermatology.
A new "smart bandage" has been developed that can detect early tissue damage from pressure ulcers before they are visible to the human eye.
Patients with moderate-to-severe psoriasis showed significant recovery after a single dose of an experimental human antibody treatment that targets interleukin-23, a study showed.
The Food and Drug Administration (FDA) has approved the first biosimilar product, Zarxio (filgrastim-sndz; Sandoz).
The Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab; Bristol-Myers Squibb) for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.
A skin test may help diagnose Alzheimer's and Parkinson's diseases by detecting potential biomarkers, new research has shown.
The Federal Trade Commission (FTC) has announced that the agency is actively challenging several marketers of mobile apps promoted to detect symptoms of melanoma (even in its early stages) due to deceptive claims.
Eli Lilly and Company and Incyte announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis.
The Food and Drug Administration (FDA) has approved Covidien's VenaSeal system for permanent treatment of varicose veins of the legs by sealing the affected superficial veins with an adhesive.
Treatment with pimecrolimus for eczema was found unlikely to increase the risk of cancer in children, according to a post-marketing study.
Galderma announced the availability of Soolantra (ivermectin) Cream for the the treatment of rosacea.
The Food and Drug Administration (FDA) has accepted for review the sNDA for Xeljanz (tofacitinib citrate; Pfizer) 5mg and 10mg tablets for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
The Food and Drug Administration (FDA) has approved Cohera Medical's TissuGlu Surgical Adhesive, the first tissue adhesive for internal use.
Galderma announced the launch of Restylane Silk, the first dermal filler approved for lip augmentation and correction of perioral rhytids in patients over 21 years old.
Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
ParaPRO announced that the Food and Drug Administration (FDA) has approved an expanded age range for Natroba (spinosad) Topical Suspension, to include children 6 months of age and older who have pediculosis capitis (head lice).
BioMonde announced the launch of BioBag, a biosurgical medical device for wound debridement.
Suneva Medical announced that the Food and Drug Administration (FDA) has approved Bellafill for the treatment of acne scars in patients over age 21.
Galderma announced the launch of Benzac Acne Solutions, their first over-the-counter (OTC) acne regimen.
Galderma announced that the Food and Drug Administration (FDA) has approved Soolantra (ivermectin) Cream for the topical treatment of inflammatory lesions of rosacea.
The Food and Drug Administration (FDA) has granted accelerated approval for Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with unresectable or metastatic melanoma who are unresponsive to other drugs.
Apira Science announced that it has received over-the-counter (OTC) clearance from the Food and Drug Adminstration (FDA) for its iGrow Hair Growth System to promote hair growth in women with Fitzpatrick skin phototypes I to IV and with Ludwig Baldness Scale Classifications of I to II.
Genentech has submitted a New Drug Application (NDA) to the FDA for cobimetinib in combination with Zelboraf (vemurafenib) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
Merz Dermatology announced that Naftin (naftifine HCl) Gel 2% and Naftin (naftifine HCl) Cream 2% have been approved for the treatment of interdigital type tinea pedis in pediatric patients aged 12-17 years.
Hospital-acquired conditions (HACs) experienced a 17% decline from 2010-2013 and a 9% reduction from 2012-2013, according to figures released by the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS).
Galderma announced the launch of its Cetaphil Baby line, featuring five new products.
Amgen and AstraZeneca announced results from the Phase 3 AMAGINE-2 study evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis.
Valeant announced that the Food and Drug Administration (FDA) has approved Onexton (clindamycin phosphate and benzoyl peroxide) Gel for the once-daily treatment of comedonal and inflammatory acne in patients aged ≥12 years old.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to dupilumab (Regeneron and Sanofi) for the treatment of adults with moderate-to-severe atopic dermatitis who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate.
Celgene announced results from two PALACE Phase 3 clinical trials with Otezla (apremilast) for the treatment of adults with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Bristol-Myers Squibb Company announced results from the Phase 3 CheckMate-066 study comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma.
Galderma announced new packaging of the Cetaphil RestoraDerm product line to reflect the newly renamed Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming Moisturizer.
Amgen and AstraZeneca announced results from AMAGINE-3, a Phase 3 trial evaluating brodalumab in patients with moderate-to-severe plaque psoriasis.
Rogaine, a brand of McNeil Consumer, announced the launch of Women's Rogaine 5% Minoxidil Topical Aerosol, the first once-daily treatment for female pattern hair loss.
Novartis announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has unanimously voted in support of the approval of AIN457 (secukinumab) for the treatment of moderate to severe plaque psoriasis.
New findings from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) indicate significantly better persistency and lower rates of discontinuation therapy with Stelara (ustekinumab; Jannsen Biotech) compared with anti-tumor necrosis factor (TNF)-alpha treatments.
Amgen announced that its Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared to Humira (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint.
Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis (pJIA), and psoriasis.
AbbVie announced that the Food and Drug Administration (FDA) has approved the use of Humira (adalimumab) for moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) to reducing signs and symptoms in patients aged ≥2 years.
Ranbaxy announced the launch of Absorica (isotretinoin) 25mg and 35mg capsules for the treatment of severe recalcitrant nodular acne in patients ≥12 years old.
LEO Pharma announced that Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension has been approved for the treatment of plaque psoriasis of the scalp in patients aged 12-17 years.
AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease for patients ≥6 years old.
Celgene announced that the Food and Drug Administration (FDA) has approved Otezla (apremilast) for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
AbbVie announced results from the Phase 3 PIONEER 1 study with Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS).
The Food and Drug Administration (FDA) has granted accelerated approval for Keytruda (pembrolizumab; Merck) for the treatment of advanced or unresectable melanoma in patients who are no longer responsive to other drugs.
Eli Lilly and Company announced results from its Phase 3 UNCOVER studies of ixekizumab for the treatment of moderate-to-severe plaque psoriasis, in which ixekizumab was found to be superior to etanercept.
Auxilium announced positive results from a Phase 2a study of Xiaflex (collagenase clostridium histolyticum [CCH]) for the treatment of edematous fibrosclerotic panniculopathy (EEP), also known as cellulite.
Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.
CareFusion announced the launch of its ChloraPrep 1mL applicator, the latest addition to the ChloraPrep line.
The FDA has approved the New Drug Application (NDA) for Acticlate (doxycycline hyclate) for the treatment of susceptible infections including adjunctive therapy in severe acne.
Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis (pJIA), and severe, recalcitrant, disabling psoriasis.
Novartis announced results from two Phase 3 trials evaluating secukinumab in patients with moderate-to-severe plaque psoriasis.
PuraCap announced the introduction of EpiCeram Airless Pump, the latest addition to the EpiCeram line.
Aqua Pharmaceuticals announced the launch of Cordran Ointment (flurandrenolide) 0.05% for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
The FDA has issued a warning that certain over-the-counter (OTC) topical acne medications may cause rare but serious and potentially life-threatening allergic reactions or severe irritation.
Quest Products announced the launch of ProVent Eczema and Psoriasis Spray indicated to help minimize the appearance of skin conditions often associated with eczema and psoriasis.
Bristol-Myers Squibb's Phase 3 study, CheckMate -066 evaluating nivolumab vs. dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early due to an analysis demonstrating evidence of superior overall survival in patients receiving nivolumab compared to the control arm.
Valeant announced that the FDA has issued clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine, a submucosal implant for lip augmentation and dermal implantation for correction of perioral rhytids in patients >21 years old.
Quest Products announced the launch of ProVent Rosacea Moisturizing Creme indicated to help reduce the appearance of skin often associated with rosacea and other skin conditions.
The FDA announced a final order reclassifying sunlamp products and ultraviolet (UV) lamps designed for use in sunlamp products from low-risk (Class I) to moderate-risk (Class II) devices.
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Over $11.1 million worth of unapproved drugs have been seized by the U.S. marshals per request of the FDA and the U.S. Attorney for the Southern District of Ohio.
Mean adjusted annual health care costs associated with newly diagnosed psoriasis exceeds $4,000.
Pfizer announced top-line results from two pivotal Phase 3 trials, evaluating the efficacy and safety of Xeljanz (tofacitinib) for the treatment of moderate-to-severe plaque psoriasis.
Antares Pharma announced the publication of results from its crossover study comparing the relative bioavailability, safety, and tolerability of Otrexup (methotrexate) to oral methotrexate (MTX) in adults with rheumatoid arthritis in the Annals of the Rheumatic Diseases.
Understanding the treatment options and related side effects of UV therapy can guide the right therapeutic choice for patients with psoriasis.
Quest Products has announced that it will now distribute Alocane Emergency Burn Gel (Lidocaine HCl 4%), a topical gel for pain and itch relief.
Valeant announced that Luzu (luliconazole) Cream is now available.
Research on a technique for detecting the earliest spread of melanoma has confirmed that the procedure significantly prolongs patients' survival rates compared with traditional watch-and-wait techniques.
Merz Pharmaceuticals announced the launch of Mederma PM Intensive Overnight Scar Cream (dimethicone 2%), a new cream designed to work at night.
Janssen R&D announced results from X-PLORE, a Phase 2b study of guselkumab (CNTO 1959) in patients with moderate to severe plaque psoriasis.
Celgene announced the release of new research findings on Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 Phase 3 studies in patients with moderate to severe plaque psoriasis.
Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Galderma announced results from two Phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopusular rosacea.
Pierre Fabre Dermatologie has received FDA marketing approval of Hemangeol (propranolol HCl) oral solution for the treatment of proliferating infantile hemangioma requiring systemic therapy.
Amgen announced results from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene reduced the size of injected tumors and non-injected metastasized tumors.
Widespread use of pyrethrins- or pyrethroid-based products appears to have resulted in selection pressure for a highly-resistant strain of human head lice in North America.
For patients with advanced melanoma, nivolumab may improve overall survival and has an acceptable long-term safety profile.
Indoor tanning is common among high school students and is linked to engaging in other risky behaviors.
Excessive tanning may indicate the presence of psychiatric distress.
Adjuvant high-dose vitamin D3 is beneficial for patients with chronic urticaria.
Onset Dermatologics announced the launch of Minocin (minocycline HCl) 75mg pellet-filled capsules, a new dosage strength for Minocin.
Older men are more likely to have a whole-body skin exam done by their physician if they watch a video on skin self-examination and skin awareness.
Teledermatology is reliable for initial triage of patients, according to a study published online.
Onset Dermatologics announced the availability of Tretin-X (tretinoin) Cream 0.075%. Tretin-X Cream is indicated for the topical treatment of acne vulgaris.
FDA has approved Retin-A Micro (tretinoin; Valeant) gel microsphere 0.08%, a new strength of Retin-A Micro gel.
Agent Orange (2,3,7,8-tetrachlorodibenzodioxin) exposure is associated with increased incidence of nonmelanotic invasive skin cancer.
Galderma has announced that in a one-year, open-label, non-comparative study, Mirvaso (brimonidine) topical gel was demonstrated to be safe and effective when used once daily for up to 12 months.
Botanical extracts may be helpful in the treatment of hyperpigmentation, although identification of hyperpigmentation subtype may be important for treatment prognosis.
Scientists might be able to offer "hair-challenged" males a new glimmer of hope when it comes to reversing baldness.
Medac Pharma announced that the FDA has accepted for review its New Drug Application (NDA) for its lead product candidate MPI-2505 (methotrexate).
Lasers may be a promising treatment for onychomycosis but larger studies are needed to determine optimal treatment conditions.
Men with higher levels of melatonin may have a lower risk of developing prostate cancer.
- Necessary Procedure Leads to Assault and Battery Charges
- Certain Antibiotics May Up Diabetes Risk
- FDA: Life-Threatening Interaction Possible Between Antivirals, Amiodarone
- Study: Abuse, Addiction, Poisoning Diagnoses Decrease with Reformulated Oxycontin
- Study: Pregnant, Breastfeeding Women Not Consuming Enough of This Nutrient
- Public Health Emergency Declared in IN Following HIV Outbreak
- Study: Hospital Readmissions, Length of Stay Greater for C. diff Patients
- Does the Aviation Industry Need Better Mental Health Screening?
- National Strategy to Fight Superbugs Released by the White House
- Gene Mutation May Explain Severe Flu in Healthy Children